Investigating how specific gene mutations affect the progression of blood cancers.
Official title: BCOR/PRC1.1 Inactivation In Splicing Factor Mutant MDS Progression
Funded at Dana-Farber Cancer Inst · NIH-11070408 · Data updated 2026-11-12
This study is looking at how certain genetic changes, specifically BCOR mutations, affect the progression of acute myeloid leukemia (AML) that starts from myelodysplastic syndrome (MDS), to help us understand how these changes work with other mutations and impact the disease for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 8, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $250,507 |
| NIH project number | 5K08CA282965-02 |
| Project ID | NIH-11070408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or myelodysplastic syndrome, particularly those with specific genetic mutations like U2AF1 and BCOR.
✕Less likely to help
Patients without acute myeloid leukemia or myelodysplastic syndrome, or those without the relevant genetic mutations, may not benefit from this research.
What this research studies
This research focuses on understanding the role of BCOR mutations in the progression of acute myeloid leukemia (AML) that arises from myelodysplastic syndrome (MDS). By studying a large cohort of patients and using advanced genetic models, the research aims to uncover how these mutations interact with other genetic factors, particularly U2AF1 mutations, to influence disease severity and progression. The approach includes analyzing patient samples and utilizing genetically engineered mice to replicate the disease conditions, providing insights into the underlying mechanisms of AML development.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potentially new treatment strategies for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promising results in understanding genetic mutations in blood cancers, indicating that this approach may yield valuable insights.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Vedula, Rahul — Dana-Farber Cancer Inst
- Study coordinator: Vedula, Rahul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.